A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Public ClinicalTrials.gov record NCT05227703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Study identification
- NCT ID
- NCT05227703
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 391 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2022 (Actual)
- Primary completion
- Aug 15, 2024 (Actual)
- Completion
- Sep 11, 2024 (Actual)
- Last update posted
- Oct 28, 2025
2022 – 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bentonville, Arkansas | Bentonville | Arkansas | 72712-3873 | — |
| Bellflower, California | Bellflower | California | 90706-7079 | — |
| La Habra, California | La Habra | California | 90631-3842 | — |
| San Diego, California | San Diego | California | 92103-2209 | — |
| Sherman Oaks, California | Sherman Oaks | California | 91403-1747 | — |
| Torrance, California | Torrance | California | 90504-4432 | — |
| New Haven, Connecticut | New Haven | Connecticut | 06519-1109 | — |
| Homestead, Florida | Homestead | Florida | 33032-8187 | — |
| Miami, Florida | Miami | Florida | 33122-1335 | — |
| Miami Lakes, Florida | Miami Lakes | Florida | 33016-1553 | — |
| Miami Springs, Florida | Miami Springs | Florida | 33166-7225 | — |
| Atlanta, Georgia | Atlanta | Georgia | 30331-2012 | — |
| Savannah, Georgia | Savannah | Georgia | 31405-5701 | — |
| Chicago, Illinois | Chicago | Illinois | 60640-5017 | — |
| Chicago, Illinois | Chicago | Illinois | 60641 | — |
| Berlin, New Jersey | Berlin | New Jersey | 08009 | — |
| Marlton, New Jersey | Marlton | New Jersey | 08053 | — |
| Charlotte, North Carolina | Charlotte | North Carolina | 28211-4849 | — |
| Austin, Texas | Austin | Texas | 78754-5122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05227703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05227703 live on ClinicalTrials.gov.